IBI3033

DRUG3 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Atopic DermatitisHealthy Participants

Phase 1

A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants

Active, not recruitingNCT07311226

Innovent Biologics (Suzhou) Co. Ltd.Healthy Participants

Start: 2025-12-31End: 2026-06-30Updated: 2026-05-22

A Mutiple-dose Study of IBI3033 in Healthy Participants

Active, not recruitingNCT07456839

Innovent Biologics (Suzhou) Co. Ltd.Healthy Participants

Start: 2026-03-18End: 2026-11-13Updated: 2026-05-26

A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis

Not yet recruitingNCT07549984

Innovent Biologics (Suzhou) Co. Ltd.Atopic Dermatitis

Start: 2026-04-30End: 2027-03-25Target: 16Updated: 2026-04-24